Yes, I was very surprised to see this fall on results as they were excellent and exactly what I expected. The product division has huge potential relative to LBL's current size.
- Forums
- ASX - By Stock
- LBL
- Ann: December 2016 Appendix 4D & Financial Report
Ann: December 2016 Appendix 4D & Financial Report, page-3
Featured News
Add LBL (ASX) to my watchlist
(20min delay)
|
|||||
Last
62.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.67M |
Open | High | Low | Value | Volume |
63.0¢ | 63.0¢ | 62.0¢ | $81.38K | 131.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 17770 | 61.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
63.0¢ | 3865 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 17770 | 0.615 |
3 | 34393 | 0.610 |
1 | 1650 | 0.605 |
1 | 828 | 0.600 |
2 | 116722 | 0.595 |
Price($) | Vol. | No. |
---|---|---|
0.630 | 3865 | 1 |
0.635 | 1366 | 1 |
0.640 | 2271 | 2 |
0.645 | 6789 | 1 |
0.650 | 4630 | 1 |
Last trade - 15.59pm 12/11/2024 (20 minute delay) ? |
Featured News
LBL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online